Win For Barr In Glaucoma Drug IP Suit Upheld By Fed. Circ.

Law360, New York (March 18, 2014, 7:50 PM EDT) -- The Federal Circuit on Tuesday affirmed a lower court's ruling that generics maker Barr Laboratories Inc. did not infringe two Alcon Research Ltd. patents covering the glaucoma drug Travatan Z, but reversed the court's finding that the patents were invalid.

Alcon claimed that Barr's abbreviated new drug application for a generic version of the drug would infringe its patents, but the appeals court concluded that the company did not prove infringement.

"We affirm the district court's holding that Alcon failed to prove by a preponderance of...
To view the full article, register now.